Myriad Genetics Inc.

MYGN

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0000899923

B

second fifth of 370 graded peers in healthcare

rank 106 of 370; percentile 28.5; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk



Scoreboard	
Profitability	A percentile 8.7
Solvency	C/D percentile 58.7
Growth and financing	C percentile 56.1
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $706.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Feb 24, 2026 256 days before the rescan; latest periodic filing 10-Q received Nov 6, 2026
Last close	$5.91 2026-11-06; market equity $566.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 8.7						
Gross profitability	81.6%	32.3%		8.0	365	2025-12-31
Return on invested capital	not computable	9.3%				
prior invested-capital observation is 1096 days earlier						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(42.4%)	(6.6%)	9.4	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five consecutive annual gross margins are required					
Solvency, sleeve percentile 58.7					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(5.88)	(0.37)	54.2	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.49x	2.94x	63.2	828	2025-12-31
Growth and financing, sleeve percentile 56.1					
Revenue growth, three-year compound	6.7%	10.0%	56.2	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 12					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(16.2%)	2.2%	78.1	696	2025-12-31
Net share issuance, one year	2.4%	2.5%	34.0	630	2026-02-19


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 29,700,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
101	Travere Therapeutics, Inc. (TVTX)	27.1	B	
102	Tela Bio, Inc. (TELA)	27.4	B	fortress balance sheet
103	Alphatec Holdings, Inc. (ATEC)	27.6	B	
104	Avalo Therapeutics, Inc. (AVTX)	27.9	B	dilution, degenerate inputs
105	Agape ATP Corp. (ATPC)	28.2	B	late filer
106	Myriad Genetics Inc. (MYGN)	28.5	B	fortress balance sheet
107	DocGo Inc. (DCGO)	28.7	B	late filer, fortress balance sheet
108	Agios Pharmaceuticals, Inc. (AGIO)	29.0	B	short runway
109	Healthcare Services Group Inc. (HCSG)	29.3	B	
110	Tandem Diabetes Care Inc. (TNDM)	29.5	B	
111	Cadre Holdings, Inc. (CDRE)	29.8	B	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(46.4%)	(2.1%)	18
Distance from 52-week high	(25.2%)	(30.5%)	56
EBIT to enterprise value	(66.5%)	(1.5%)	11
Free cash flow yield	(26.7%)	(1.0%)	20
Book value to price	0.47	0.29	66
Sales to price	1.45	0.30	86
Composite equity issuance, five years	22.9%	21.4%	51
Relative strength against the sector, log excess return	(0.79)	(0.19)	18

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$107.1M
Operating cash flow, four quarters	-$19.9M
Months of runway	64.6
Days since last periodic filing	1 (10-Q received Nov 6, 2026)
Median daily dollar volume, 63 sessions	$6.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$576.6M	2025-12-31	2026-02-24	10-K	26-000018
2	assets	us-gaap:Assets	$706.6M	2025-12-31	2026-02-24	10-K	26-000018
3	operating income	us-gaap:OperatingIncomeLoss	-$387.2M	2025-12-31	2026-02-24	10-K	26-000018
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$395.1M	2025-12-31	2026-02-24	10-K	26-000018
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-$29.2M	2025-12-31	2026-02-24	10-K	26-000018
6	total debt	us-gaap:LongTermDebt	$119.9M	2025-12-31	2026-02-24	10-K	26-000018
7	book equity	us-gaap:StockholdersEquity	$368.0M	2025-12-31	2026-02-24	10-K	26-000018
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$149.6M	2025-12-31	2026-02-24	10-K	26-000018
9	total debt	us-gaap:LongTermDebt	$0	2022-12-31	2023-03-01	10-K	23-000011
10	book equity	us-gaap:StockholdersEquity	$885.8M	2022-12-31	2026-02-24	10-K	26-000018
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$56.9M	2022-12-31	2025-02-28	10-K	25-000019
12	net income	us-gaap:NetIncomeLoss	-$365.9M	2025-12-31	2026-02-24	10-K	26-000018
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.8M	2025-12-31	2026-02-24	10-K	26-000018
14	assets	us-gaap:Assets	$1.0B	2024-12-31	2026-02-24	10-K	26-000018
15	current assets	us-gaap:AssetsCurrent	$332.6M	2025-12-31	2026-02-24	10-K	26-000018
16	current liabilities	us-gaap:LiabilitiesCurrent	$133.8M	2025-12-31	2026-02-24	10-K	26-000018
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.1B	2025-12-31	2026-02-24	10-K	26-000018
18	liabilities	us-gaap:Liabilities	$338.6M	2025-12-31	2026-02-24	10-K	26-000018

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	depreciation amortization	us-gaap:Depreciation	$19.5M	2025-12-31	2026-02-24	10-K	26-000018
20	operating income	us-gaap:OperatingIncomeLoss	-$257.4M	2023-12-31	2026-02-24	10-K	26-000018
21	interest expense	us-gaap:InterestExpense	$2.9M	2023-12-31	2024-02-28	10-K	24-000018
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$824.5M	2025-12-31	2026-02-24	10-K	26-000018
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$837.6M	2024-12-31	2026-02-24	10-K	26-000018
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$753.2M	2023-12-31	2026-02-24	10-K	26-000018
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$678.4M	2022-12-31	2025-02-28	10-K	25-000019
26	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$45.3M	2022-12-31	2023-03-01	10-K	23-000011
27	depreciation amortization	us-gaap:Depreciation	$11.6M	2022-12-31	2025-02-28	10-K	25-000019
28	operating income	us-gaap:OperatingIncomeLoss	-$140.6M	2022-12-31	2025-02-28	10-K	25-000019
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$140.6M	2022-12-31	2025-02-28	10-K	25-000019
30	income tax	us-gaap:IncomeTaxExpenseBenefit	-$28.6M	2022-12-31	2025-02-28	10-K	25-000019
31	current assets	us-gaap:AssetsCurrent	$274.6M	2022-12-31	2024-02-28	10-K	24-000018
32	current liabilities	us-gaap:LiabilitiesCurrent	$137.2M	2022-12-31	2024-02-28	10-K	24-000018
33	current assets	us-gaap:AssetsCurrent	$484.8M	2021-12-31	2023-03-01	10-K	23-000011
34	current liabilities	us-gaap:LiabilitiesCurrent	$204.3M	2021-12-31	2023-03-01	10-K	23-000011
35	assets	us-gaap:Assets	$1.1B	2023-12-31	2025-02-28	10-K	25-000019
36	assets	us-gaap:Assets	$1.2B	2022-12-31	2024-02-28	10-K	24-000018
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	93,508,165	2026-02-19	2026-02-24	10-K	26-000018
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	91,309,064	2025-02-21	2025-02-28	10-K	25-000019

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.